Research Study

A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)
Principal Investigator 
Theodore Steiner

Overview

ClinicalTrials.gov# 
NCT03595566
Status 
Recruiting
Study Start/End 
Nov 28, 2019 to Oct 20, 2023
Locations 
Diamond Health Care Centre
Name/Title 
Hannah Peters, Research Coordinator
Phone 
604-875-4111 ext.69771
Email Address 
hannah.peters@ubc.ca
Purpose of Study 

The purpose of this study is to compare ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.